Results 1 to 10 of about 3,861 (173)

Phosphate Binding with Sevelamer Preserves Mechanical Competence of Bone Despite Acidosis in Advanced Experimental Renal Insufficiency. [PDF]

PLoS ONE, 2016
INTRODUCTION:Phosphate binding with sevelamer can ameliorate detrimental histomorphometric changes of bone in chronic renal insufficiency (CRI). Here we explored the effects of sevelamer-HCl treatment on bone strength and structure in experimental CRI ...
Jarkko Jokihaara, Ilkka H Pörsti, Harri Sievänen, Peeter Kööbi, Pekka Kannus, Onni Niemelä, Russell T Turner, Urszula T Iwaniec, Teppo L N Järvinen   +8 more
doaj   +3 more sources

Association between sevelamer use and outcomes in acute kidney injury with hyperphosphataemia: evidence from the MIMIC-IV [PDF]

Frontiers in Pharmacology
BackgroundHyperphosphataemia is consistently linked to adverse clinical outcomes in Acute Kidney Injury (AKI). Sevelamer, a non-calcium phosphate binder widely used in chronic kidney disease (CKD), has not been adequately evaluated for efficacy in AKI ...
Shuzhen Suo, Qilin Yang, Weiyan Chen, Liya Luo, Yongkang Song, Chunxiang Ling, Jianzhong Wang, Deliang Wen, Changbo Liu   +8 more
doaj   +2 more sources

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study

Kidney Diseases, 2022
Introduction: Previous studies suggested that sevelamer carbonate is well tolerated with a favorable efficacy and safety profile in both dialysis and nondialysis patients in Europe; however, the efficacy remains controversial, and few studies have ...
Wei Chen, Hua-Feng Liu, Qin-Kai Chen, Ming-Hui Zhao, Xiao-Nong Chen, Hong Liu, Jian-Xin Wan, Shao-Mei Li, Meng-Hua Chen, Chun Dai, Hong-Bin Shi, Jia-Li Wei, Hong-Wen Zhao, Li-Hua Wang, Gang Long, Wan-Hong Lu, Ying Tang, Jun-Wei Yang, Li-Ying Cao, Dong-Xing Tang, Yu-Qiong Yang, Xue-Qing Yu   +21 more
doaj   +2 more sources

Protein-bound Uremic Toxin Lowering Effects of Sevelamer in Hyperphosphatemic Hemodialysis Patients: A Multicenter Randomized Controlled Trial [PDF]

Kidney Medicine
Rationale & Objective: p-Cresyl sulfate (pCS) is an important protein-bound uremic toxin associated with high cardiovascular mortality in patients receiving long-term hemodialysis (HD). Data regarding pCS lowering and the pleiotropic effects of sevelamer
Napas Srifa, Jeerath Phannajit, Patchara Tanateerapong, Kamonrat Chongthanakorn, Sipanan Thamratnopkoon, Wannasit Wathanavasin, Supat Vanichakarn, Sookruethai Lekhyananda, Yingyos Avihingsanon, Kearkiat Praditpornsilpa, Somchai Eiam-Ong, Paweena Susantitaphong   +11 more
doaj   +2 more sources

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients [PDF]

Kidney International Reports
Introduction: Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract.
Li Wang, Li Zuo, Ming Shi, Leyi Gu, Kunling Ma, Pei Wang, Yu Wang, Qun Luo, Menghua Chen, Ping Zhang, Hongli Jiang, Guisen Li, Weifeng Zhang, Yingxue Cathy Liu, Qing Zhao   +14 more
doaj   +3 more sources

Repurposing of sevelamer as a novel antidote against aluminum phosphide poisoning: An in vivo evaluation

Heliyon, 2023
Aluminum phosphide (AlP) is widely used for protecting grains from pests. AlP releases toxic phosphine gas (PH3) while exposed to humidity. Poisoning with these tablets is dangerous and can cause death or serious injuries. Up to now, no definite antidote
Reza Heidari, Hamid Reza Mohammadi, Fazel Goudarzi, Fatemeh Farjadian   +3 more
doaj   +1 more source

Lower gastrointestinal bleeding in a patient receiving sevelamer: Case report

SAGE Open Medical Case Reports, 2021
Phosphate binders such as sevelamer are widely used in patients with chronic kidney disease to lower serum phosphate levels. We present a case of a 67-year-old woman with lower gastrointestinal bleeding after 9 days of using sevelamer carbonate (Renvela ®
Tessa S Schoot, Tessa EH Römkens, Ellen K Hoogeveen   +2 more
doaj   +1 more source

Sevelamer Attenuates Bioprosthetic Heart Valve Calcification

Frontiers in Cardiovascular Medicine, 2021
Objective: Sevelamer hydrochloride is a phosphate binder used to treat hyperphosphatemia in chronic kidney disease (CKD) patients that can reduce valvular and vascular calcification. The aim of this study was to examine the effects of sevelamer treatment
Zhen Meng, Zhe Li, Erli Zhang, Li Zhang, Qingrong Liu, Yongjian Wu   +5 more
doaj   +1 more source

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis

Microorganisms, 2020
Despite the use of various pharmacotherapeutic strategies, fibrosis due to nonalcoholic steatohepatitis (NASH) remains an unsatisfied clinical issue. We investigated the effect of sevelamer, a hydrophilic bile acid sequestrant, on hepatic fibrosis in a ...
Yuki Tsuji, Kosuke Kaji, Mitsuteru Kitade, Daisuke Kaya, Koh Kitagawa, Takahiro Ozutsumi, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Tadashi Namisaki, Kei Moriya, Takemi Akahane, Hitoshi Yoshiji   +12 more
doaj   +1 more source

Comparison of sevelamer and calcium carbonate in prevention of hypomagnesemia in hemodialysis patients

International Journal of Preventive Medicine, 2021
Background: Chronic kidney disease (CKD) is a life-threatening disease with numerous complications. Hemodialysis (HD) patients are prone to magnesium deficiency due to malnutrition, which can cause cardiovascular complications and increase mortality. The
Elahe Jandaghi, Maliheh Yarmohammadi, Raheb Ghorbani, Tahereh Jalali, Ali Khadjeh Salehani, Peiman Mohammad Khani   +5 more
doaj   +1 more source